• MaxCyte to Participate in Upcoming Investor Conferences

    Source: Nasdaq GlobeNewswire / 12 Nov 2021 07:00:01   America/Chicago

    GAITHERSBURG, Md., Nov. 12, 2021 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT, MXCN), a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development and commercialization, today announced Company management will participate in the following investor conferences:

    • Consilium Strategic Communications 9th Annual Healthcare Conference 2021
      Panel discussion on Monday, November 15th at 8:50 a.m. Eastern Time
    • Stifel 2021 Virtual Healthcare Conference
      Fireside chat on Tuesday, November 16th at 8:00 a.m. Eastern Time
    • Stephens Annual Investment Conference
      Fireside chat on Monday, November 29th at 12:00 p.m. Eastern Time

    Live and archived webcasts of the events will be available on the “Events” section of the MaxCyte investor relations website at https://investors.maxcyte.com/.

    About MaxCyte

    MaxCyte is a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development and commercialization. Over the past 20 years, we have developed and commercialized our proprietary Flow Electroporation® platform, which facilitates complex engineering of a wide variety of cells. Our ExPERT™ platform, which is based on our Flow Electroporation technology, has been designed to support the rapidly expanding cell therapy market and can be utilized across the continuum of the high-growth cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes: three instruments, the ATx™, STx™ and GTx™; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a robust worldwide intellectual property portfolio.

    MaxCyte Contacts:

    US IR Adviser 
    Gilmartin Group+1 415-937-5400
    David Deuchler, CFAir@maxcyte.com 
      
    Nominated Adviser and Joint Corporate Broker 
    Panmure Gordon+44 (0)20 7886 2500
    Emma Earl / Freddy Crossley 
    Corporate Broking 
    Rupert Dearden 
      
    UK IR Adviser+44 (0)203 709 5700
    Consilium Strategic Communicationsmaxcyte@consilium-comms.com 
    Mary-Jane Elliott 
    Chris Welsh 

    Primary Logo

Share on,